Home Cart Sign in  
Chemical Structure| 38520-57-9 Chemical Structure| 38520-57-9

Structure of N-acetylcysteine amide
CAS No.: 38520-57-9

Chemical Structure| 38520-57-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces ROS production.

Synonyms: NACA; N-acetyl-L-Cysteine amide; Nac amide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of N-acetylcysteine amide

CAS No. :38520-57-9
Formula : C5H10N2O2S
M.W : 162.21
SMILES Code : O=C(N)[C@@H](NC(C)=O)CS
Synonyms :
NACA; N-acetyl-L-Cysteine amide; Nac amide
MDL No. :MFCD01696115
InChI Key :UJCHIZDEQZMODR-BYPYZUCNSA-N
Pubchem ID :10176265

Safety of N-acetylcysteine amide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312+P330-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HB1.F3.CD neural stem cells 1 mM 72 hours To evaluate the effect of NACA on the viability of CRAd-S-pk7-loaded neural stem cells, the results showed that NACA significantly increased the viability of neural stem cells and enhanced viral replication. PMC3831038
U87 glioma cells 1 mM 72 hours To evaluate the effect of NACA on the viability of U87 glioma cells, the results showed that NACA did not significantly increase the viability of U87 cells. PMC3831038
human retinal pigment epithelial cells 1 mM 8 hours To evaluate the effect of N-acetylcysteine amide on oxidative stress-induced microparticle release, results showed that NACA significantly reduced oxidative stress-induced microparticle release. PMC4736743

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Drosophila Drosophila model Oral 40 μg/ml Starting from 2 days and continued NACA treatment completely rescued the climbing defects in tau RNAi flies, indicating that aberrant ROS accumulations are driving this phenotype. PMC11809452
Mice VP-PXR transgenic mice Intraperitoneal injection 200 mg/kg Once, 1 hour before HS/R NACA treatment attenuated HS-induced hepatic injury, as shown by reduced histological necrosis and decreased serum ALT levels. PMC6717545
Drosophila melanogaster Drosophila larvae and adults Supplemented in food 75 μg/mL Continuous administration for 20 days NACA significantly ameliorated the accumulation of LDs in the fat body, impaired larval movement and adult climbing ability, and reduced adult longevity caused by imidacloprid. PMC7568275
Wistar rats Aβ1-42 peptide-induced Alzheimer's-like pathology model Intraperitoneal injection 75 mg/kg Once daily for 7 days NACA treatment reversed cognitive deficits and reduced oxidative stress in the hippocampus and prefrontal cortex. Western blot analysis and immunohistochemistry demonstrated NACA's neuroprotective effects on neurogenesis, expression of neurofibrillary tangles, β-amyloid peptide, synaptophysin, neuronal morphology, and gliosis. PMC10454451
Nude mice Intracranial glioma xenograft model Intraperitoneal injection 250 mg/kg/day Once daily for 5 days To evaluate the effect of combined treatment of NACA and CRAd-S-pk7-loaded neural stem cells on the survival of glioma-bearing mice, the results showed that the combined treatment significantly prolonged the survival of mice and increased intratumoral viral distribution. PMC3831038
CD-1 mice HIV-associated dementia model Intraperitoneal injection 250mg/kg body weight Once daily for 5 days NACA significantly protected animals from oxidative stress-induced damage and restored BBB permeability PMC2873898
Drosophila melanogaster Adult virgin female flies Oral 300 µg/mL 5 hours NACA treatment improved the movement and survival of larvae exposed to spinosad, indicating a causal role for oxidative stress in the mode of action of spinosad at low doses. PMC8863376

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.16mL

1.23mL

0.62mL

30.82mL

6.16mL

3.08mL

61.65mL

12.33mL

6.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories